Discontinued drugs in 2005: Pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs

Expert Opinion on Investigational Drugs

Volumn 15, Issue 12, 2006, Pages 1497-1505

  Lee, Kenneth K C ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Antiarthritics; Biological agents; Dermatological agents; Economics; Gastrointestinal drugs; New drug development

Indexed keywords

4 AMINO 5 CHLORO N (8 METHYL 8 AZABICYCLO[3.2.1]OCT 3ALPHA YL) 2 (1 METHYL 2 BUTYNYLOXY)BENZAMIDE; A 002; AD 827; AFG 495; AKU 517; ANTIASTHMATIC AGENT; ANTIRHEUMATIC AGENT; AR H044277; AR H047108; AVE 5883; AZD 0865; BDD 11602; DERMATOLOGICAL AGENT; GASTROINTESTINAL AGENT; GLYCEROL LAURATE; GLYLORIN; IP 501; ISIS 104838; JTE 607; LERDELIMUMAB; LY 333013; METELIMUMAB; MT 201; NALTREXONE; NCX 1022; P 45; P 53; PGN 1164; PLACEBO; PTI 901; QAN 747; ROFECOXIB; S 3013; SIM 688; SIM 916; T 100; TAK 201; UNINDEXED DRUG;

ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; DRUG INDICATION; DRUG LEGISLATION; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG WITHDRAWAL; ECONOMIC EVALUATION; ECZEMA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEPATITIS C; HUMAN; ICHTHYOSIS VULGARIS; IRRITABLE COLON; LIVER CIRRHOSIS; OSTEOARTHRITIS; PSORIASIS; SKIN DISEASE; STRUCTURE ANALYSIS;

ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS; CLINICAL TRIALS; DERMATOLOGIC AGENTS; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; HYPERSENSITIVITY; LUNG DISEASES; SKIN DISEASES;

EID: 33845225645     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.12.1497     Document Type: Article

References (8)

1. FITZGERALD GA: Anticipating change in drug development: the emerging era of translational medicine and therapeutics. Nat. Rev. (2005) 4:815-818.
2. DI MASI JA, HANSEN RW, GRABOWSKI HG: The price of innovation: new estimates of drug development costs. J. Health Econ. (2003) 22(2):151-185.
3. MIWA H, OHKURA R, MURAI T et al.: Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection - comparison with omeprazole and lansoprazole. Aliment. Pharmacol, Ther. (1999) 13:741-746.
4. INABA T, MIZUNO M, KAWAI K et al.: Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J. Gastroenterol. Hepato. (2002) 17:748-753.
5. LEE VWY, CHAN AKW, LEE KKC, WAYE MMY, CHAN FKL: Clinical impact of CYP2C19 genetic polymorphism on two proton pump inhibitors in triple therapy of eradicating helicobacter pylori in Hong Kong Chinese subjects. 15th World Congress of Pharmacology and 2006 Annual Meeting of the Pacific Rim Association for Clinical Pharmacogenetics, China (July 2006) (Oral Presentation).
6. CARO JJ, SALAS M, WARD A. Healing and relapse rates in gastroesophageal relux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin. Ther. (2001) 23:998-1017.
7. WONG BCY, WONG WM, YEE YK et al.: Rabeprazole-based 3-day and 7-day triple therapy vs. orneprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2001) 15:1959-1965.
8. NURMOHAMED MT, DIJKMANS BAC: Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs (2005) 65(5):661-694.